Dual Antiplatelet Therapy to Inhibit Coronary Atherosclerosis and Myocardial Injury in Patients With Necrotic High-Risk Coronary Plaque Disease

Trial Profile

Dual Antiplatelet Therapy to Inhibit Coronary Atherosclerosis and Myocardial Injury in Patients With Necrotic High-Risk Coronary Plaque Disease

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 05 May 2017

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms DIAMOND
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 May 2017 Planned End Date changed from 1 Jan 2018 to 1 May 2018.
    • 02 May 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top